Pear Therapeutics sets the stage for a fruitful 2022, forecasting a five-fold boost in revenue

Nicole DeFeudis

Editor

Not so bad for its first earnings report. In a quarterly call on Monday, Pear Therapeutics CEO Corey McCann celebrated the company’s “strong financial results …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pear Therapeutics sets the stage for a fruitful 2022, forecasting a five-fold boost in revenue

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Some FDA medical device staff reinstated just days after receiving pink slips

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Alcon tried to sink Aurion's IPO in 'Valentine's Day massacre,' new lawsuits say

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

How AI can address ongoing challenges in the life sciences industry

Pear Ther­a­peu­tics sets the stage for a fruit­ful 2022, fore­cast­ing a five-fold boost in rev­enue

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Pear Therapeutics sets the stage for a fruitful 2022, forecasting a five-fold boost in revenue